4CPS-109 Experience of regorafenib use in metastatic colorectal cancer

BACKGROUND: Regorafenib has been approved for the treatment of patients with previously treated metastatic colorectal cancer (mCRC), and may be considered as a treatment for selected patients. PURPOSE: To evaluate the efficacy and safety of regorafenib treatment in patients with mCRC. MATERIAL AND M...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Eur J Hosp Pharm
Hlavní autoři: Mateos, E, Alamo, AM, Vaswani, A Ramchandani, Pin, M Lombardero, López, ME Luján, García, JA Rodriguez, Villalustre, C Otero, Vera, D Fernandez
Médium: Artigo
Jazyk:Inglês
Vydáno: BMJ Group 2018
Témata:
Section 4: Clinical pharmacy services
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7535196/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/ejhpharm-2018-eahpconf.200
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky